ReviewTransactions of the Royal Society of Tropical Medicine and Hygiene2018
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).
Review in Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Epidemiology and costs of dengue in Thailand: A systematic literature review.PLoS neglected tropical diseases · 2022Pooled it
- Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18-50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial.Human vaccines & immunotherapeutics · 2025Trial
- Secondary Analysis of the Efficacy and Safety Trial Data of the Tetravalent Dengue Vaccine in Children and Adolescents in Colombia.The Pediatric infectious disease journal · 2020Trial
- Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.The American journal of tropical medicine and hygiene · 2019Trial
- Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.BMC infectious diseases · 2018Trial
- Seroepidemiological surveillance of neutralizing antibodies against dengue virus serotypes among healthy adults in Bangkok, Thailand.One health (Amsterdam, Netherlands) · 2025Article
- Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.The American journal of tropical medicine and hygiene · 2023Article
- Risk factors for infection with chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional seroprevalence survey.PLoS neglected tropical diseases · 2022Article
- Dengue virus seroprevalence study in Bangphae district, Ratchaburi, Thailand: A cohort study in 2012-2015.PLoS neglected tropical diseases · 2022Article
- Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Article
- Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains.Nature communications · 2021Article
- Dengue in Western Uganda: a prospective cohort of children presenting with undifferentiated febrile illness.BMC infectious diseases · 2020Observational
- Risk of dengue virus infection according to serostatus in individuals from dengue endemic areas of Mexico.Scientific reports · 2020Article
- The east coast districts are the possible epicenter of severe dengue in Sabah.Journal of physiological anthropology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue seroprevalence data in the literature is limited and the available information is difficult to compare between studies because of the varying survey designs and methods used. We assessed dengue seropositivity across 14 countries using data from 15 trials conducted during the development of a tetravalent dengue vaccine between October 2005 and February 2014. Participants' dengue seropositivity (n=8592) was determined from baseline (before vaccination) serum samples at two centralized laboratories with the plaque reduction neutralization test (PRNT50). Seropositivity rates generally increased with age in endemic settings. Although seropositivity rates varied across geographical areas, between countries, and within countries by region, no major differences were observed for given age groups between the two endemic regions, Latin America and Asia-Pacific. Seropositivity rates were generally stable over time. The proportion of participants who had only experienced primary infection tended to be higher in younger children than adolescents/adults. These results will help inform and guide dengue control strategies in the participating countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.